Close Menu

NEW YORK(GenomeWeb) – Australian proteomics firm Proteomics International Laboratories today said it plans to offer up to A$6 million (US$5.2 million) of its shares in an initial public offering on the Australian Stock Exchange.

The firm said in a prospectus that it seeks to raise between A$4 million and A$6 million through an offering of up to 30 million shares of its stock at A$.20 per share. The proceeds will be used to drive growth in each of its three business units: analytical services, diagnostics, and therapeutics.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Kelvin Droegemeier, the director of the White House Office of Science and Technology Policy, is the new acting director of the US National Science Foundation.

An opinion piece at the Guardian discusses the state of SARS-CoV-2 testing in the UK.

Wired reports the University of California, Berkeley's Innovative Genomics Institute has transformed itself into a diagnostic lab to run SARS-CoV-2 tests.

In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.